Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

NCT06561347 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Zanubrutinib
DRUG: Bendamustine
DRUG: Rituximab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]